Acquired myeloma-associated Type III hyperlipidaemia treated by nonmyeloablative HLA-identical sibling allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET): evidence of engraftment without manifestation of ET in recipient

Chee, Lynette; Spearing, Ruth; Morris, Christine M.; McDonald, Michael P.; Hanrahan, Vickie; Ebbett, AM; Scott, Russell S.; Florkowski, C.M.; Walmsley, T A; Patton, W. N.

doi:10.1038/sj.bmt.1704973

Cited by 7 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of a recent study demonstrated a higher prevalence of dyslipidemia (54%) among individuals even with SMM compared to a healthy control group (32%) [ 101 ]. Interestingly, several case reports of acquired myeloma-related Frederickson’s type III hyperlipoproteinemia (increased remnant or intermediate-density lipoproteins, IDL) and type V hyperlipoproteinemia (increased chylomicron and very low-density lipoproteins, VLDL) hyperlipoproteinemia have been published [ 130 , 131 ]. Many studies have implicated paraproteins in the development of MM associated dyslipidemia [ 101 , 129 , 132 ].…”

Section: Metabolic Syndromementioning

confidence: 99%

Metabolic Disorders in Multiple Myeloma

Gavriatopoulou

Paschou

Ntanasis‐Stathopoulos

et al. 2021

IJMS

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematological malignancy and is attributed to monoclonal proliferation of plasma cells in the bone marrow. Cancer cells including myeloma cells deregulate metabolic pathways to ensure proliferation, growth, survival and avoid immune surveillance, with glycolysis and glutaminolysis being the most identified procedures involved. These disorders are considered a hallmark of cancer and the alterations performed ensure that enough energy is available for rapid cell proliferation. An association between metabolic syndrome, inflammatory cytokinesand incidence of MM has been also described, while the use of metformin and statins has been identified as a positive prognostic factor for the disease course. In this review, we aim to present the metabolic disorders that occur in multiple myeloma, the potential defects on the immune system and the potential advantage of targeting the dysregulated pathways in order to enhance antitumor therapeutics.

show abstract

Section: Metabolic Syndromementioning

confidence: 99%

Metabolic Disorders in Multiple Myeloma

Gavriatopoulou

Paschou

Ntanasis‐Stathopoulos

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…A review of 53 cases by Misselwitz et al [34] that compared hyperlipidaemic MM patients to patients with MM and a normal lipid status concluded a higher incidence of IgA paraprotein (53 vs. 21%), skin xanthomas (70%), and hyperviscosity syndrome (26 vs. 2-6%) in the former patient group [33]. There are also several case reports of acquired myelomarelated phenotypical presentation of Frederickson's type III (raised remnant or intermediate-density lipoproteins; IDL) and type V (raised chylomicron and very low-density lipoproteins) hyperlipoproteinaemia available in the literature [38][39][40]. Dyslipidaemia associated with MM may be relatively refractory to conventional lipid-lowering medications but responsive to successful MM treatment [34,35,41].…”

Section: Hyperlipidaemiamentioning

confidence: 99%

The Association between Metabolic Syndrome and Multiple Myeloma

et al. 2020

View full text Add to dashboard Cite

Multiple myeloma (MM) is a haematological malignancy arising from monoclonal proliferation of plasma cells in the bone marrow, resulting in the presence of paraproteins or M-protein in serum. The involvement of paraproteins produced by malignant plasma cells in the development of hyperlipidaemia and low-HDL cholesterol has been described, as has an association with MM and obesity, hypertension, and type 2 diabetes mellitus, and insulin resistance, that is, features of the metabolic syndrome (MS). There is an association between MS components, inflammatory cytokines, and the development of MM, and some drugs used in the treatment of MS such as statins and metformin may improve outcomes in MM.

show abstract

“…Patients with myotonic dystrophy can also exhibit PSX, when the linkage disequilibrium is with APOE2 instead of APOE4 [ 32 ]. Finally, PSX are observed in patients with multiple myeloma [ 49 , 50 ], a disease associated with interference in the catabolism of lipoprotein by the paraprotein [ 51 ]. Except for myotonic dystrophy, these disorders were not represented in our study.…”

Section: Discussionmentioning

confidence: 99%

Palmar Striated Xanthomas in Clinical Practice

Roy

Gaudet

Brisson

2022

Journal of the Endocrine Society

View full text Add to dashboard Cite

Introduction The aim of this study was to assess the occurrence of palmar striated xanthomas (PSX) in a wide spectrum of lipid disorders ranging from very severe hypercholesterolemia (homozygous familial hypercholesterolemia) to very severe hypertriglyceridemia (chylomicronemia). Methods This study involved 3,382 dyslipidemic Caucasian adult patients (1,856 men and 1,526 women) seen at the Chicoutimi Hospital Lipid Clinic (Quebec, Canada), covering a wide range of lipid disorders, from severe hypertriglyceridemia to severe hypercholesterolemia. Categorical variables were compared using the Pearson χ2 statistic, whereas univariate analysis of variance (ANOVA) or nonparametric Kruskal-Wallis were used for continuous variables. Results A total of 5.1% (173/3382) of the studied patients presented PSX, a majority of them (67.1%) being women. PSX were observed in 18.8% of patients with dysbetalipoproteinemia and also among 14.1% of hypertriglyceridemic patients with partial lipoprotein lipase deficiency, 3.7% of patients with chylomicronemia and in all of those with homozygous familial hypercholesterolemia. Overall, 10.7% of patients with PSX did not meet dysbetalipoproteinemia diagnosis criteria. Conclusion According to our study, the PSX prevalence estimate among patients without dysbetalipoproteinemia would be around 10% and they could be observed in a wide spectrum of lipid disorders associated with recurrent or sustained remnant lipoprotein accumulation.

show abstract

Acquired myeloma-associated Type III hyperlipidaemia treated by nonmyeloablative HLA-identical sibling allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET): evidence of engraftment without manifestation of ET in recipient

Cited by 7 publications

References 7 publications

Metabolic Disorders in Multiple Myeloma

Metabolic Disorders in Multiple Myeloma

The Association between Metabolic Syndrome and Multiple Myeloma

Palmar Striated Xanthomas in Clinical Practice

Contact Info

Product

Resources

About